Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
49 hedge funds and large institutions have $30.5M invested in Agile Therapeutics in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 19 reducing their positions, and 16 closing their positions.
656% more call options, than puts
Call options by funds: $363K | Put options by funds: $48K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less funds holding
Funds holding: 64 → 49 (-15)
33% less capital invested
Capital invested by funds: $45.7M → $30.5M (-$15.2M)
47% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 19
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$258K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$242K |
| 3 |
BlackRock
New York
|
+$183K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$79.2K |
| 5 |
SGI
Summit Global Investments
Bountiful,
Utah
|
+$18.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$905K |
| 2 |
Millennium Management
New York
|
-$638K |
| 3 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$321K |
| 4 |
Goldman Sachs
New York
|
-$305K |
| 5 |
Morgan Stanley
New York
|
-$283K |
AGRX Hedge Fund Activity: Q3 2021 in Review
49 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q3 2021, worth a combined $30.5M — down 33% from $45.7M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AGRX and 1 opened new positions — a net loss of 15 holders — while 19 trimmed existing stakes and 10 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $258K. The largest seller was Renaissance Technologies, cutting an estimated $905K.
- 49 institutional investors held Agile Therapeutics (AGRX) as of Q3 2021, down from 64 in Q2 2021.
- Funds reported $30.5M of Agile Therapeutics stock for Q3 2021, down 33% quarter-over-quarter.
- 1 fund opened new Agile Therapeutics positions in Q3 2021 and 16 closed out, a net change of -15 holders.
- The largest Agile Therapeutics buyer in Q3 2021 was D.E. Shaw & Co, an estimated $258K added.
- The largest Agile Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $905K sold.
Based on aggregated 13F filings for Q3 2021.